Drug research

XEN496

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as ezogabine; retigabine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEENCT04912856	XENE	Phase 3	Terminated	2023-11-17Actual
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyNCT04639310	XENE	Phase 3	Terminated	2023-05-16Actual

XENETerminatedPrimary completion: 2023-11-17 · Actual

Trial details

XENETerminatedPrimary completion: 2023-05-16 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.